4D Molecular Therapeutics (FDMT) EPS (Basic) (2020 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly EPS (Basic) of -$1.01 for Q1 2026, down 17.39% year-over-year from -$1.22 in Q1 2025, and down 401.71% quarter-over-quarter from $0.33 in Q4 2025.
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) EPS (Basic) (2020 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported EPS (Basic) for 7 consecutive years, with -$1.01 the latest figure, recorded in Q1 2026.
- In Q1 2026, EPS (Basic) fell 17.39% year-over-year to -$1.01; the TTM figure through Mar 2026 stood at -$2.36 (up 25.32% YoY), while the FY2025 annual figure was -$2.42, up 18.9% from the prior year.
- EPS (Basic) eased to -$1.01 in Q1 2026 per FDMT's latest filing, from $0.33 in the prior quarter.
- Across five years, EPS (Basic) topped out at $0.33 in Q4 2025 and bottomed at -$1.01 in Q3 2025.
- Historically, EPS (Basic) has averaged -$0.74 across 5 years, with a median of -$0.83 in 2023.
- Annual changes were most pronounced in 2024 — EPS (Basic) sank 225.16% — and 2025, when it surged 136.36%.
- 4D Molecular Therapeutics' EPS (Basic) stood at -$0.85 in 2022, then increased by 2.52% to -$0.83 in 2023, then retreated by 11.61% to -$0.92 in 2024, then soared by 136.36% to $0.33 in 2025, then plunged by 401.71% to -$1.01 in 2026.
- Business Quant data shows FDMT's EPS (Basic) at -$1.01 in Q1 2026, $0.33 in Q4 2025, and -$1.01 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 7.70 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -1.96 |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -3.06 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 2.12 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 1.23 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 0.18 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.06 |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - | -1.04 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -1.04 |
| Mar 31, 2026 | -1.01 |
| Dec 31, 2025 | 0.33 |
| Sep 30, 2025 | -1.01 |
| Jun 30, 2025 | -0.98 |
| Mar 31, 2025 | -0.86 |
| Dec 31, 2024 | -0.92 |
| Sep 30, 2024 | -0.79 |
| Jun 30, 2024 | -0.63 |
| Mar 31, 2024 | -0.66 |
| Dec 31, 2023 | -0.83 |
| Sep 30, 2023 | -0.24 |
| Jun 30, 2023 | -0.77 |
| Mar 31, 2023 | -0.88 |
| Dec 31, 2022 | -0.85 |
| Sep 30, 2022 | -0.79 |
| Jun 30, 2022 | -0.87 |
| Mar 31, 2022 | -0.82 |
| Dec 31, 2021 | -0.90 |
| Sep 30, 2021 | -0.82 |